GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (OTCPK:NBRVF) » Definitions » Shares Outstanding (EOP)

Nabriva Therapeutics (Nabriva Therapeutics) Shares Outstanding (EOP) : 3.23 Mil (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Nabriva Therapeutics's shares outstanding for the quarter that ended in Jun. 2023 was 3.23 Mil.

Nabriva Therapeutics's quarterly shares outstanding increased from Mar. 2023 (3.20 Mil) to Jun. 2023 (3.23 Mil). It means Nabriva Therapeutics issued new shares from Mar. 2023 to Jun. 2023 .

Nabriva Therapeutics's annual shares outstanding increased from Dec. 2021 (2.27 Mil) to Dec. 2022 (3.20 Mil). It means Nabriva Therapeutics issued new shares from Dec. 2021 to Dec. 2022 .


Nabriva Therapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Nabriva Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Shares Outstanding (EOP) Chart

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.38 0.84 2.27 3.20

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.58 3.02 3.20 3.20 3.23

Competitive Comparison of Nabriva Therapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Nabriva Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nabriva Therapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's Shares Outstanding (EOP) falls into.



Nabriva Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Nabriva Therapeutics  (OTCPK:NBRVF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Nabriva Therapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Nabriva Therapeutics (Nabriva Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Executives
Hogan H Michael Iii officer: Chief Executive Officer C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
David Maggio officer: Chief Financial Officer 15950 N. DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Mark Corrigan director
Broom Colin Md officer: Chief Executive Officer 119 FRINGETREE DRIVE, WEST CHESTER PA 19380
Stephen W Webster director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Carrie L. Bourdow officer: Director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Theodore R Schroeder officer: Chief Executive Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
J. Christopher Naftzger officer: General Counsel and Corp Sec 633 LOWTHER ROAD, LEWISBERRY PA 17339
Christine J. Guico-pabia officer: Chief Medical Officer C/O NABRIVA THERAPEUTICS PLC, 414 COMMERCE DRIVE, SUITE 120, FORT WASHINGTON PA 19034
Lisa Dalton director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Daniel Dolan officer: Chief Financial Officer C/O NABRIVA THERAPEUTICS PLC, 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Francesco Maria Lavino officer: Chief Commercial Officer 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Robert Crotty officer: General Counsel & Corp Sec. 1301 2ND AVE, SEATTLE WA 98101